CytoDyn Inc’s final mTNBC report indicates 980% increase in 12-month overall survival with…
The late-stage biotech firm additionally reported as much as a 660% improve in modified progression-free survival at 12 months in 30 metastatic triple-negative breast most cancers sufferers
CytoDyn Inc shared an replace on its beforehand…